• Program Objectives

    "The Microbiome: Emerging Opportunities for Biopharma" will fill a critical need for a rigorous understanding of the latest microbiome research and the evidence supporting specific applications in the biotech and pharmaceutical industries. Participants will come away with a framework to guide their thinking about how to evaluate existing microbiome programs, identify emerging areas of opportunity and set strategic priorities for research, discovery and investment.

  • Curriculum

    The program will feature an engaging mix of presentations and participant discussions across a wide-range of microbiome topics and issues including:

    • How state-of-the-art platforms and capabilities can drive insights for R&D: metagenomics, metatranscriptomics, metabolomics
    • Deriving therapeutic hypotheses from microbiome bioinformatics: Insights into microbial communities and function
    • Prospects for microbiome-based biomarkers and therapeutics
    • The chemistry of the microbiome and community functional pathways
    • How microbiome research can add value to “traditional” biopharma programs (e.g., connections between the microbiome and existing programs/therapeutics in inflammation, immunity, infectious diseases, cancer)
    • Leveraging human microbiome community resources: Cohorts and data banks
    • Emerging technologies, applications and avenues of investigation
    • The landscape of disease applications of the microbiome: Prospects and time horizons for different conditions
    • Current evidence and future applications of fecal microbiota transplantation (FMT)
    • Emerging regulatory framework
  • Who Should Participate?

    "The Microbiome: Emerging Opportunities for Biopharma" is designed for industry leaders (in scientific or business roles) who make operational, strategic or investment decisions related to microbiome research.  It is most appropriate for professionals in the biotech and pharmaceutical industries, or related investing, venture capital and other professional services.

  • Program Fee

    Program Dates: TBA

    Program Fee: $3,650

    Team Discount: 20% discount off full program price for teams of 3 or more. Please contact one of our program advisors to learn more at executive_education@hms.harvard.edu or 617-432-1538.


  • Request more information

Kurt Isselbacher Professor of Medicine at Harvard Medical School
Core Institute Member of the Broad Institute of MIT and Harvard
Co-Director of the Broad Institute's Infectious Disease and Microbiome Program
Hsien Wu and Daisy Yen Wu Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
Associate Professor, Department of Microbial Pathogenesis, Microbial Sciences Institute, Yale University School of Medicine
Vice President, Immunology Research and Development, The Janssen Pharmaceutical Companies of Johnson & Johnson
Chief, Infectious Diseases, VA Palo Alto Health Care System
Thomas C. and Joan M. Merigan Professor Depts. of Medicine and of Microbiology and Immunology, Stanford University